InnoCare Pharma Shares Orelabrutinib Clinical Trial Results at EHA Congress

AI-generated NewsSnap summary based on source reporting.
Published: 2026-06-15
Category: health
Source: FirstWord Pharma (via GLOBE NEWSWIRE)
Original source

InnoCare Pharma presented over 40 clinical studies for its BTK inhibitor, orelabrutinib, at the European Hematology Association 2026 Congress. New global Phase 1/2 data demonstrated the drug's effectiveness and safety in treating chronic lymphocytic leukemia/small lymphocytic lymphoma patients. These findings further support its use across various hematological malignancies.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai